Global Ganja Report

Progressives coast to coast breathed a heavy sigh of relief as Joe Biden took the oath of office, ending the turbulent and reactionary rule of Donald Trump over the past four years.

But hemp cultivation, like the rewriting and replacement of NAFTA, was one of the few areas that actually saw positive change in the Trump years—with bipartisan support. The 2018 Farm Bill that re-legalized the crop after generations of prohibition bore Trump’s signature.

And there are fears that Biden could mean a return to the Washington consensus of a corporate-friendly “free trade” status quo ante, shorn even of the limited populist measures of the Trump era.

For small farmers, including some hemp cultivators, Biden’s choice to lead the US Department of Agriculture (USDA) may provide a case in point.

As the cannabis industry is embraced by corporate power and finance capital, the patenting of strains, products and applications is an increasing concern. But the international patchwork of legality makes for a confusing environment. Illegality has served as a paradoxical break on privatizing of varieties. Growers and advocates are devising means to protect the genetic commons in the new cannabis order.

Hundreds of cannabis possession charges have been dismissed in Texas in recent weeks because police don't have labs that can differentiate between marijuana and newly legal hemp. The governor, attorney general and politicians are up in arms about it. Other states are updating their test kits to distinguish between CBD and THC in confiscated samples.

Having just undertaken a "critical study" of CBD, the non-psychoactive cannabinoid held to have multifarious medicinal applications, the World Health Organization is now opening such a study on THC. Stigmatized due to its psychoactive properties and currently in the shadow of the suddenly sexy CBD, tetrahydrocannabinol shows its own potential for application by the medical industry.

A British Columbia firm which is one of Canada's leading licensed producers of medical marijuana has entered a partnership with the national subsidiary of Sandoz, a global leader in the pharmaceutical industry. The deal is being hailed as a milestone that signals the arrival of cannabis in the corporate economy.

Both the absurdity of the war on drugs and the depravity of the current administration in Washington are illustrated by the maddening case of Alvin Queen, an internationally acclaimed jazz drummer who was denied entry to the US due to a minor drug arrest when he was still a teen—despite the fact that he was born in the country!

A cannabis decriminalization law took effect in Switzerland Oct. 1. From the start of this month, possession of up to 10 grams is punishable only by a fine of 100 Swiss Francs (approximately $110) for those over the age of 18. The new law is an effort to unify what had been a patchwork of policies that varied by locality. The measure is expected to save money by cutting back on the 30,000 cannabis-related cases that make their way to the courts each year.